Calyxt announces agreement with evologic technologies to scale production of its plant-based ingredients

Agreement will power speed-to-scale strategy to meet the growing interest in high-quality sustainable ingredients across the cosmeceutical, nutraceutical and pharmaceutical markets roseville, minn. , oct. 6, 2022 /prnewswire/ -- calyxt, inc. (nasdaq: clxt), a plant-based synthetic biology company, today announced that it has signed an agreement with its first manufacturing partner, evologic technologies gmbh, to further develop and scale calyxt's proprietary plant cell matrix™ (pcm™) technology platform.
CLXT Ratings Summary
CLXT Quant Ranking